We retrospectively analyzed the role of the dose level of CMF (cyclophosphamide, methotrexate, and fluorouracil) in postoperative adjuvant chemotherapy for breast cancer and in chemotherapy for metastatic breast cancer. There was a clear dose-response effect, indicating that CMF was useful only when given in a full or nearly full dose (greater than or equal to 85 per cent of the planned dose). Those given adjuvant therapy with 12 cycles of CMF at this dose level had a five-year relapse-free survival of 77 per cent, as compared with 45 per cent of patients treated only with radical mastectomy (P = 0.0001). In contrast, a subgroup receiving less than 65 per cent of the planned dose had a five-year survival without relapses of 48 per cent and a five-year survival with relapses of 67 per cent. These results are similar to those observed in a control group. With each dose level, the results at five years were influenced by the number of axillary lymph nodes involved but not by menopausal status. Our findings indicate that it is necessary to administer combination chemotherapy at a full dose to achieve clinical benefit.
This article has been cited by other articles:
Olopade, O. I., Grushko, T. A., Nanda, R., Huo, D.
(2008). Advances in Breast Cancer: Pathways to Personalized Medicine. Clin. Cancer Res.
14: 7988-7999
[Abstract][Full Text]
Anderson, J. R., Cain, K. C., Gelber, R. D.
(2008). Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables. JCO
26: 3913-3915
[Full Text]
Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., Asnis-Alibozek, A.
(2008). Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. JCO
26: 556-562
[Abstract][Full Text]
Snyder, R. L, Stringham, D. J
(2007). Pegfilgrastim-Induced Hyperleukocytosis. The Annals of Pharmacotherapy
41: 1524-1530
[Abstract][Full Text]
Felman, I. E.
(2007). Impact of Toxicity Assumptions on Socioeconomic Analysis of Breast Cancer Chemotherapy. JCO
25: 2331-2332
[Full Text]
Griggs, J. J., Culakova, E., Sorbero, M. E.S., van Ryn, M., Poniewierski, M. S., Wolff, D. A., Crawford, J., Dale, D. C., Lyman, G. H.
(2007). Effect of Patient Socioeconomic Status and Body Mass Index on the Quality of Breast Cancer Adjuvant Chemotherapy. JCO
25: 277-284
[Abstract][Full Text]
Poole, C. J., Earl, H. M., Hiller, L., Dunn, J. A., Bathers, S., Grieve, R. J., Spooner, D. A., Agrawal, R. K., Fernando, I. N., Brunt, A. M., O'Reilly, S. M., Crawford, S. M., Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A., Harvey, P., McAdam, K., Foster, L., Leonard, R. C.F., Twelves, C. J., the NEAT Investigators and the SCTBG,
(2006). Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer. NEJM
355: 1851-1862
[Abstract][Full Text]
Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W.-Y., Grann, V. R., Hershman, D. L.
(2006). Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the Elderly. JCO
24: 2368-2375
[Abstract][Full Text]
Mayer, M.
(2006). Listen to all the voices: an advocate's perspective on early access to investigational therapies. Clin Trials
3: 149-153
[Abstract]
Partridge, A. H.
(2006). Non-adherence to endocrine therapy for breast cancer. Ann Oncol
17: 183-184
[Full Text]
Hershman, D., McBride, R., Jacobson, J. S., Lamerato, L., Roberts, K., Grann, V. R., Neugut, A. I.
(2005). Racial Disparities in Treatment and Survival Among Women With Early-Stage Breast Cancer. JCO
23: 6639-6646
[Abstract][Full Text]
Demicheli, R., Miceli, R., Moliterni, A., Zambetti, M., Hrushesky, W. J. M., Retsky, M. W., Valagussa, P., Bonadonna, G.
(2005). Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol
16: 1449-1457
[Abstract][Full Text]
Griggs, J. J., Sorbero, M. E. S., Lyman, G. H.
(2005). Undertreatment of Obese Women Receiving Breast Cancer Chemotherapy. Arch Intern Med
165: 1267-1273
[Abstract][Full Text]
Bonadonna, G., Moliterni, A., Zambetti, M., Daidone, M. G., Pilotti, S., Gianni, L., Valagussa, P.
(2005). 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ
330: 217-
[Abstract][Full Text]
Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, Kenneth. S., Knowling, M. A., Coppin, C. M. L., Weir, L., Gelmon, K., Le, N., Durand, R., Coldman, A. J., Manji, M.
(2005). Locoregional Radiation Therapy in Patients With High-Risk Breast Cancer Receiving Adjuvant Chemotherapy: 20-Year Results of the British Columbia Randomized Trial. JNCI J Natl Cancer Inst
97: 116-126
[Abstract][Full Text]
Schott, A., Hayes, D. F.
(2004). Adjuvant Chemotherapy for Elderly Women With Hormone Receptor-Positive Breast Cancer: An Old(er) Problem. JCO
22: 4660-4662
[Full Text]
Talarico, L., Chen, G., Pazdur, R.
(2004). Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug Administration. JCO
22: 4626-4631
[Abstract][Full Text]
Hortobagyi, G. N.
(2004). What Is the Role of High-Dose Chemotherapy in the Era of Targeted Therapies?. JCO
22: 2263-2266
[Full Text]
Bonadonna, G., Zambetti, M., Moliterni, A., Gianni, L., Valagussa, P.
(2004). Clinical Relevance of Different Sequencing of Doxorubicin and Cyclophosphamide, Methotrexate, and Fluorouracil in Operable Breast Cancer. JCO
22: 1614-1620
[Abstract][Full Text]
Yee, K. W.L., Pater, J. L., Pho, L., Zee, B., Siu, L. L.
(2003). Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?. JCO
21: 1618-1623
[Abstract][Full Text]
Partridge, A. H., Avorn, J., Wang, P. S., Winer, E. P.
(2002). Adherence to Therapy With Oral Antineoplastic Agents. JNCI J Natl Cancer Inst
94: 652-661
[Abstract][Full Text]
Ferreira Filho, A. F., Di Leo, A., Paesmans, M., Beauduin, M., Vindevoghel, A., Michel, J., Focan, C., Awada, A., Cardoso, F., Dolci, S., Bartholomeus, S., Piccart, M. J.
(2002). The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative doses across institutions. Ann Oncol
13: 416-421
[Abstract][Full Text]
Colleoni, M., Rocca, A., Sandri, M. T., Zorzino, L., Masci, G., Nole, F., Peruzzotti, G., Robertson, C., Orlando, L., Cinieri, S., Braud, F. d., Viale, G., Goldhirsch, A.
(2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol
13: 73-80
[Abstract][Full Text]
Hortobagyi, G. N
(2001). Progress in Systemic Chemotherapy of Primary Breast Cancer: an Overview. J Natl Cancer Inst Monogr
2001: 72-79
[Abstract][Full Text]
Fornier, M. N., Seidman, A. D., Theodoulou, M., Moynahan, M. E., Currie, V., Moasser, M., Sklarin, N., Gilewski, T., D'Andrea, G., Salvaggio, R., Panageas, K. S., Norton, L., Hudis, C.
(2001). Doxorubicin Followed by Sequential Paclitaxel and Cyclophosphamide versus Concurrent Paclitaxel and Cyclophosphamide: 5-Year Results of a Phase II Randomized Trial of Adjuvant Dose-dense Chemotherapy for Women with Node-positive Breast Carcinoma. Clin. Cancer Res.
7: 3934-3941
[Abstract][Full Text]
Sargent, D. J., Goldberg, R. M., Jacobson, S. D., Macdonald, J. S., Labianca, R., Haller, D. G., Shepherd, L. E., Seitz, J. F., Francini, G.
(2001). A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients. NEJM
345: 1091-1097
[Abstract][Full Text]
Wood, W. C.
(2001). Challenges Facing Clinical Research. Ann. Surg. Oncol.
8: 471-476
[Full Text]
Ackland, S. P., Anton, A., Breitbach, G. P., Colajori, E., Tursi, J. M., Delfino, C., Efremidis, A., Ezzat, A., Fittipaldo, A., Kolaric, K., Lopez, M., Viaro, D.
(2001). Dose-Intensive Epirubicin-Based Chemotherapy Is Superior to an Intensive Intravenous Cyclophosphamide, Methotrexate, and Fluorouracil Regimen in Metastatic Breast Cancer: A Randomized Multinational Study. JCO
19: 943-953
[Abstract][Full Text]
Hudis, C., Fornier, M., Riccio, L., Lebwohl, D., Crown, J., Gilewski, T., Surbone, A., Currie, V., Seidman, A., Reichman, B., Moynahan, M., Raptis, G., Sklarin, N., Theodoulou, M., Weiselberg, L., Salvaggio, R., Panageas, K.S., Yao, T.J., Norton, L.
(1999). 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study. JCO
17: 1118-1118
[Abstract][Full Text]
Czuczman, M. S., Grillo-Lopez, A. J., White, C. A., Saleh, M., Gordon, L., LoBuglio, A. F., Jonas, C., Klippenstein, D., Dallaire, B., Varns, C.
(1999). Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy. JCO
17: 268-268
[Abstract][Full Text]
Subramanyan, S., Kennedy, M. J.
(1998). Breast Cancer: High-Dose Therapy. The Oncologist
3: 289-299
[Abstract][Full Text]
Foote, M.
(1998). The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?. The Oncologist
3: 365-368
[Full Text]
Evans, R. S., Pestotnik, S. L., Classen, D. C., Clemmer, T. P., Weaver, L. K., Orme, J. F., Lloyd, J. F., Burke, J. P.
(1998). A Computer-Assisted Management Program for Antibiotics and Other Antiinfective Agents. NEJM
338: 232-238
[Abstract][Full Text]
Brockstein, B., Williams, S.
(1996). High-dose chemotherapy with autologous stem cell rescue for breast cancer: yesterday, today and tomorrow. Stem Cells
14: 79-89
[Abstract]
Summerhayes, M.
(1995). Review : Amifostine and other chemoprotective agents in cancer chemotherapy: A brief review. J Oncol Pharm Pract
1: 21-31
[Abstract]
Del Mastro, L., Costantini, M., Bianco, A. R., Newman, M. D., Evans, R. A., Bonadonna, G., Valagussa, P., Henderson, I. C.
(1995). Adjuvant Chemotherapy in Breast Cancer. NEJM
333: 596-597
[Full Text]
Bonadonna, G., Valagussa, P., Moliterni, A., Zambetti, M., Brambilla, C.
(1995). Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer -- The Results of 20 Years of Follow-Up. NEJM
332: 901-906
[Abstract][Full Text]
Wood, W. C., Budman, D. R., Korzun, A. H., Cooper, M. R., Younger, J., Hart, R. D., Moore, A., Ellerton, J. A., Norton, L., Ferree, C. R., Ballow, A. C., Frei, E., Henderson, I. C.
(1994). Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma. NEJM
330: 1253-1259
[Abstract][Full Text]
Stewart, C. F.
(1991). Pharmacodynamics and Cancer: Practical Aspects of Dose Intensity for Pharmacists. Journal of Pharmacy Practice
4: 11-19
[Abstract]
Miller, R. J.
(1989). The role of chemotherapy in the hospice patient: A problem of definition. AM J HOSP PALLIAT CARE
6: 19-26
FREI, E. III
(1983). Cancer Chemotherapy. Science
220: 254-256
Itano, J., Tanabe, P., Lum, J. L. J., Lamkin, L., Rizzo, E., Wieland, M., Sato, P., McCorkle, R., Lewis, F. M., Dodd, M.
(1983). Compliance of Cancer Patients to Therapy. West J Nurs Res
5: 5-20
Previous
